SimulectActive Ingredient(s): Basiliximab
FDA Approved: * May 12, 1998
Pharm Company: * NOVARTIS
Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. Contents 1 Uses 2 Mechanism of action 3 Chemistry 4 History 5 See also 6 References and notes Uses Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with o... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.